Organization
PharmaEngine
3 clinical trials
Clinical trial
A Phase I Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced or Metastatic Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2026-07-15
Clinical trial
Phase 1 Study of Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid TumorsStatus: Completed, Estimated PCD: 2022-05-04
Clinical trial
A Phase 1b Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced CancerStatus: Recruiting, Estimated PCD: 2025-12-31